ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
ACHIEVE LIFE SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.61+0.23 (+3.53%)
Close on Oct 19, 2026
- Market cap
- $617.64M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.3%
83M of 103M shares
Institutional holders
111
48 new, 17 sold out
Net institutional buying
61M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $175.11K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 9,903,712 | 9.20% | 13G (passive) | Apr 17, 2026 |
| Franklin Resources, Inc. | 8,878,942 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 6,625,788 | 6.50% | 13G (passive) | Apr 17, 2026 |
| Franklin Advisers, Inc. | 6,369,252 | 6.20% | 13G (passive) amendment | Apr 30, 2026 |
| JANUS HENDERSON GROUP Ltd. | 5,502,064 | 5.40% | 13G (passive) | Jun 30, 2026 |
| VHCP Co-Investment Holdings III, LLC | 5,502,064 | 5.20% | 13G (passive) | Apr 17, 2026 |
| Vivo Opportunity, LLC | 5,305,640 | 5.00% | 13G (passive) | Jul 6, 2026 |
| BlackRock, Inc. | 5,271,391 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Alyeska Fund GP, LLC | 2,982,722 | 5.60% | 13G (passive) amendment | Sep 30, 2025 |
| Leen Kawas | 2,334,176 | 6.81% | 13G (passive) | Mar 4, 2024 |
| Patrick J. Callahan III | 2,167,439 | 9.90% | 13G (passive) | Nov 15, 2022 |
| Jon Winkelried | 13,755,160 | 12.60% | 13D (active) | Apr 17, 2025 |
| venBio Global Strategic GP V, LLC | 10,737,317 | 9.99% | 13D (active) | Apr 15, 2026 |
| Logos Global Management GP LLC | 10,538,440 | 9.99% | 13G (passive) | May 11, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACHV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | 7.40% | $49.72M | New | 1.08% |
| Tpg Gp A, LLC | 6,877,580 | 6.68% | $44.91M | New | 0.90% |
| venBio Partners LLC | 5,914,720 | 5.75% | $38.62M | New | 7.44% |
| Logos Global Management LP | 5,425,000 | 5.27% | $35.43M | New | 1.53% |
| BlackRock, Inc. | 5,272,017 | 5.12% | $34.43M | +4,832,657 | 0.00% |
| Franklin Resources Inc | 4,953,220 | 4.81% | $32.34M | +584,027 | 0.01% |
| Paradigm Biocapital Advisors LP | 4,951,856 | 4.81% | $32.34M | New | 0.61% |
| Vanguard Capital Management LLC | 4,140,812 | 4.02% | $27.04M | +1,936,098 | 0.00% |
| Propel Bio Management, LLC | 4,034,018 | 3.92% | $26.34M | +247,593 | 13.79% |
| Marshall Wace, Llp | 3,770,313 | 3.66% | $24.62M | +2,751,032 | 0.02% |
| State Street Corp | 2,945,526 | 2.86% | $19.23M | +2,691,069 | 0.00% |
| Vivo Capital, LLC | 2,751,032 | 2.67% | $17.96M | New | 1.64% |
| VR Adviser, LLC | 2,751,032 | 2.67% | $17.96M | New | 0.54% |
| Jupiter Topco LLC | 2,751,032 | 2.67% | $17.96M | New | 0.01% |
| Eventide Asset Management, LLC | 2,220,000 | 2.16% | $14.50M | New | 0.19% |
| Geode Capital Management, LLC | 2,062,721 | 2.00% | $13.47M | +1,439,936 | 0.00% |
| Alyeska Investment Group, L.P. | 1,925,722 | 1.87% | $12.57M | New | 0.03% |
| Simplify Asset Management Inc. | 1,432,105 | 1.39% | $9.35M | +247,593 | 0.13% |
| Wellington Management Group Llp | 1,426,915 | 1.39% | $9.32M | New | 0.00% |
| LPL Financial LLC | 902,255 | 0.88% | $5.89M | +173,807 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 111 | 83M | 80.3% | 48 / 36 | 14 / 17 | 65M | 3M |
| Q1 2026 | 81 | 22M | 20.9% | 17 / 17 | 23 / 11 | 3M | 3M |
| Q4 2025 | 77 | 23M | 22.6% | 24 / 24 | 13 / 10 | 9M | 2M |
| Q3 2025 | 66 | 16M | 15.1% | 22 / 17 | 19 / 21 | 4M | 15M |
| Q2 2025 | 65 | 26M | 25.6% | 19 / 22 | 14 / 26 | 16M | 4M |
| Q1 2025 | 72 | 14M | 14.0% | 9 / 21 | 21 / 6 | 1M | 3M |
| Q4 2024 | 70 | 16M | 15.9% | 11 / 27 | 12 / 4 | 1M | 1M |
| Q3 2024 | 64 | 17M | 16.5% | 13 / 18 | 12 / 3 | 3M | 4M |
| Q2 2024 | 56 | 19M | 18.7% | 24 / 14 | 8 / 9 | 5M | 2M |
| Q1 2024 | 41 | 16M | 16.0% | 19 / 6 | 9 / 7 | 14M | 1M |
| Q4 2023 | 29 | 3M | 2.7% | 3 / 11 | 8 / 9 | 0M | 1M |
| Q3 2023 | 35 | 3M | 3.0% | 5 / 8 | 13 / 8 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ACHV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,108,369 | 3.02% | $20.30M | 0.00% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 2,220,000 | 2.16% | $14.50M | 0.81% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,993,533 | 1.94% | $13.02M | 0.02% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 1,432,105 | 1.39% | $9.35M | 12.11% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,349,858 | 1.31% | $8.81M | 0.08% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,095,791 | 1.06% | $7.03M | 0.61% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 957,389 | 0.93% | $6.25M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 851,832 | 0.83% | $5.47M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 731,016 | 0.71% | $4.77M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 276,242 | 0.27% | $1.45M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 261,589 | 0.25% | $1.71M | 0.11% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 189,138 | 0.18% | $1.21M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 145,507 | 0.14% | $950.16K | 0.02% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 103,456 | 0.10% | $664.19K | 0.02% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 97,174 | 0.09% | $509.19K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew D. Goldberg | CEO and President, Director | 0 | – | Apr 21, 2026 |
| Jaime Xinos | Chief Commercial Officer | 95,286 | 0.09% | Jan 30, 2026 |
| Jerry Wan | Principal Accounting Officer | 46,764 | 0.05% | Jan 30, 2026 |
| Craig Donnelly | Chief Operations Officer | 52,372 | 0.05% | Jan 30, 2026 |
| Mark K. Oki | Chief Financial Officer | 127,940 | 0.12% | Jan 30, 2026 |
| Mark Lawrence Rubinstein | Chief Medical Officer | 39,600 | 0.04% | Jan 30, 2026 |
| Erik Atkisson | Chief Legal Officer | 0 | – | Dec 8, 2025 |
| Cindy Jacobs | President & CMO | 143,214 | 0.14% | Sep 8, 2025 |
| Richard Alistair Stewart | Director | 209,490 | 0.20% | Aug 21, 2026 |
| Christopher Nathan Martin | Director | 0 | – | Jul 29, 2026 |
| Jeffrey S. Farrow | Director | 0 | – | Jul 29, 2026 |
| Thomas Sellig | Director | 0 | – | Jul 29, 2026 |
| Nancy R. Phelan | Director | 0 | – | Jul 29, 2026 |
| Aaron Royston | Director | 0 | – | Jul 29, 2026 |
| Reid Alexander Waldman | Director | 0 | – | Jul 29, 2026 |
| Lucian Iancovici | Director | 0 | – | Apr 24, 2026 |
| Thomas Braxton King | Director | 455,000 | 0.44% | Sep 8, 2025 |
| Stuart Duty | Director | 0 | – | Jun 10, 2025 |
| Bridget A. Martell | Director | 0 | – | Jun 10, 2025 |
| Kristen B. Slaoui | Director | 0 | – | Jun 10, 2025 |
| Jon Winkelried | 10% owner | – | – | Apr 24, 2026 |
| Tpg Gp A, Llc | 10% owner | – | – | Apr 24, 2026 |
| James G. Coulter | 10% owner | 6,877,580 | 6.68% | Apr 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Alistair Stewart Director | Aug 19, 2026 | Sale | −20,626 | $8.49 | $175.11K | 208,249 |
| Richard Alistair Stewart Chief Executive Officer, Director | Sep 18, 2025 | Sale | −129,501 | $2.92 | $378.14K | 228,875 |
| Richard Alistair Stewart Chief Executive Officer, Director | Sep 18, 2025 | Option exercise | +297,500 | – | – | 358,376 |
| Mark K. Oki Chief Financial Officer | Sep 18, 2025 | Sale | −50,060 | $2.92 | $146.18K | 127,940 |
| Mark K. Oki Chief Financial Officer | Sep 18, 2025 | Option exercise | +168,000 | – | – | 178,000 |
| Cindy Jacobs President & CMO | Sep 4, 2025 | Option exercise | +110,000 | – | – | 143,214 |
| Cindy Jacobs President & CMO | Sep 4, 2025 | Sale | −27,629 | $2.77 | $76.53K | 115,585 |
| Jerry Wan Principal Accounting Officer | Sep 4, 2025 | Option exercise | +34,100 | – | – | 46,764 |
| Jerry Wan Principal Accounting Officer | Sep 4, 2025 | Sale | −14,070 | $2.77 | $38.97K | 32,694 |
| Thomas Braxton King Director | Sep 4, 2025 | Option exercise | +455,000 | – | – | 455,000 |
| Thomas Braxton King Director | Sep 4, 2025 | Sale | −139,858 | $2.77 | $387.41K | 315,142 |
| Jaime Xinos Chief Commercial Officer | Sep 4, 2025 | Option exercise | +69,000 | – | – | 95,286 |
| Jaime Xinos Chief Commercial Officer | Sep 4, 2025 | Sale | −20,854 | $2.77 | $57.77K | 74,432 |
| Richard Alistair Stewart Chieve Executive Officer, Director | Mar 17, 2025 | Buy | +10,000 | $2.86 | $28.60K | 60,876 |
| Mark K. Oki Chief Financial Officer | Mar 17, 2025 | Buy | +10,000 | $2.89 | $28.90K | 10,000 |
| John Bencich CEO, Director | Aug 16, 2024 | Award | +5,000 | $3.67 | $18.35K | 100,636 |
| Cindy Jacobs President & CMO, Director | Aug 16, 2024 | Award | +2,660 | $3.67 | $9.76K | 33,214 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2024 | Award | +2,857 | $3.67 | $10.49K | 12,664 |
| John Bencich CEO, Director | Apr 19, 2024 | Option exercise | +25,000 | – | – | 101,724 |
| John Bencich CEO, Director | Apr 19, 2024 | Tax withholding | −6,088 | $4.51 | $27.46K | 95,636 |
| Jerry Wan Principal Accounting Officer | Apr 19, 2024 | Option exercise | +5,625 | – | – | 12,057 |
| Jerry Wan Principal Accounting Officer | Apr 19, 2024 | Tax withholding | −2,250 | $4.51 | $10.15K | 9,807 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 19, 2024 | Tax withholding | −10,125 | $4.51 | $45.66K | 50,876 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 19, 2024 | Option exercise | +22,500 | – | – | 61,001 |
| Cindy Jacobs President & CMO, Director | Apr 19, 2024 | Tax withholding | −3,957 | $4.51 | $17.85K | 30,554 |
| Cindy Jacobs President & CMO, Director | Apr 19, 2024 | Option exercise | +16,250 | – | – | 34,511 |
| John Bencich CEO, Director | Mar 4, 2024 | Buy | +10,000 | $4.59 | $45.90K | 76,724 |
| Richard Alistair Stewart Executive Chairman, Director | Mar 4, 2024 | Buy | +10,000 | $4.59 | $45.90K | 38,501 |
| John Bencich CEO, Director | May 30, 2023 | Buy | +5,000 | $5.50 | $27.50K | 66,730 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2023 | Tax withholding | −2,250 | $8.29 | $18.65K | 28,501 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2023 | Option exercise | +5,000 | – | – | 30,751 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2023 | Option exercise | +1,250 | – | – | 7,101 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2023 | Tax withholding | −669 | $8.29 | $5.55K | 6,432 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2023 | Tax withholding | −609 | $8.29 | $5.05K | 18,261 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2023 | Option exercise | +2,500 | – | – | 18,870 |
| John Bencich CEO, Director | Apr 28, 2023 | Option exercise | +7,500 | – | – | 63,557 |
| John Bencich CEO, Director | Apr 28, 2023 | Tax withholding | −1,827 | $8.29 | $15.15K | 61,730 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Tax withholding | −3,811 | $6.80 | $25.91K | 16,370 |
| John Bencich CEO, Director | Apr 21, 2023 | Tax withholding | −5,863 | $6.80 | $39.87K | 56,057 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Option exercise | +16,250 | – | – | 20,181 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Tax withholding | −4,819 | $6.80 | $32.77K | 15,362 |
| Jerry Wan Principal Accounting Officer | Apr 21, 2023 | Option exercise | +5,625 | – | – | 8,861 |
| Jerry Wan Principal Accounting Officer | Apr 21, 2023 | Tax withholding | −3,010 | $6.80 | $20.47K | 5,851 |
| John Bencich CEO, Director | Apr 21, 2023 | Tax withholding | −7,324 | $6.80 | $49.80K | 54,596 |
| John Bencich CEO, Director | Apr 21, 2023 | Option exercise | +25,000 | – | – | 61,920 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 21, 2023 | Tax withholding | −10,125 | $6.80 | $68.85K | 25,751 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 21, 2023 | Option exercise | +22,500 | – | – | 35,876 |
| John Bencich CEO, Director | Nov 18, 2022 | Buy | +22,000 | – | – | 36,920 |
| John Bencich CEO, Director | Aug 16, 2022 | Award | +3,059 | $4.37 | $13.37K | 14,920 |
| Cindy Jacobs President & CMO, Director | Aug 16, 2022 | Award | +1,817 | $4.37 | $7.94K | 3,931 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2022 | Tax withholding | −266 | $4.37 | $1.16K | 3,236 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2022 | Award | +2,827 | $4.37 | $12.35K | 3,502 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2022 | Tax withholding | −669 | $7.43 | $4.97K | 675 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2022 | Option exercise | +1,250 | – | – | 1,344 |
| Anthony Clarke CSO | Apr 28, 2022 | Tax withholding | −250 | $7.43 | $1.86K | 3,502 |
| Anthony Clarke CSO | Apr 28, 2022 | Option exercise | +1,000 | – | – | 3,752 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2022 | Option exercise | +2,500 | – | – | 2,723 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2022 | Tax withholding | −609 | $7.43 | $4.52K | 2,114 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2022 | Tax withholding | −2,250 | $7.43 | $16.72K | 13,376 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2022 | Option exercise | +5,000 | – | – | 15,626 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Alistair Stewart Director | Aug 19, 2026 | 20,626 | $155.11K | Aug 19, 2026 | Corporate Action |